EUFEST STUDY PDF

The European First Episode Schizophrenia Trial (EUFEST): Comparison of outcome in The European study of the effectiveness of haloperidol, amisulpride . The study helps solve the question of which category of antipsychotic medications best address impaired cognition, which affects a significant. The EUFEST study then undertook with a pragmatic open randomized-controlled trial design to compare the effectiveness of second-generation antipsychotic.

Author: Dukinos Nitaur
Country: Mayotte
Language: English (Spanish)
Genre: Personal Growth
Published (Last): 14 June 2010
Pages: 199
PDF File Size: 6.85 Mb
ePub File Size: 13.95 Mb
ISBN: 289-8-87430-290-7
Downloads: 78616
Price: Free* [*Free Regsitration Required]
Uploader: Zulkitaur

The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial.

Schizophreniform or schizoaffective disorder; 3. EUFEST assesses the effectiveness of a low dose of haloperidol versus regular doses of 4 second generation antipsychotics: SchizophreniaSchizophreniform disorderSchizoaffective disorder. We aimed to compare the effectiveness of second-generation antipsychotic drugs with that of a low dose of haloperidol, in first-episode schizophrenia.

These and other facts have stimulated discussions regarding the effectiveness of the new generation of antipsychotics. Comparisons with haloperidol showed lower risks for any-cause discontinuation with amisulpride hazard ratio [HR] 0. However, we cannot conclude that second-generation drugs are more efficacious than is haloperidol, since discontinuation rates are not necessarily consistent with symptomatic improvement.

Patients and their treating physicians were not blinded to the assigned treatment. What is the effectiveness of low doses of haloperidol and regular doses of amisulpride, olanzapine, quetiapine, and ziprasidone on loss of one year retention in patients with recent onset of schizophrenia, schizoaffective, and schizophreniform disorder? Comparison of outcome in first episode schizophrenia with different low dose antipsychotic drug regimens.

Natural history of schizophrenia. The European study of the effectiveness of haloperidol, amisulpride, olanzapine, quetiapine, and ziprasidone on loss of retention in first episode schizophrenia.

Plain English Summary Not provided at time of registration Trial website http: At regular time intervals patients are followed-up until 12 months srudy recruitment: Side effects – extrapyramidal symptoms EPS side-effect profile, sexual side effects and weight gain 3. Secondary outcome measures At regular time intervals patients are followed-up until 12 months after recruitment: Such studies were usually conducted in highly selected samples, and were generally designed and financed by the manufacturer of the drug tested.

  GNTER GRASS DIE BLECHTROMMEL PDF

The principal investigators are Prof. This pragmatic trial suggests that clinically meaningful antipsychotic treatment of first-episode of schizophrenia is achievable, for at least 1 year. At present, more than patients have been recruited and randomized in the following countries: Study information Scientific title The European study of the effectiveness of haloperidol, amisulpride, olanzapine, quetiapine, and ziprasidone on loss of retention in first episode schizophrenia Acronym EUFEST Study hypothesis What is the effectiveness of low doses of haloperidol and regular doses of amisulpride, olanzapine, quetiapine, and ziprasidone on loss of one year retention in patients with recent onset of schizophrenia, schizoaffective, and schizophreniform disorder?

PfizerAstraZenecaSanofi-Aventis. We focus on the real world treatment of first episode patients by enrolling heterogeneous patient populations, including patients who show comorbid drug abuse or who are aggressive or suicidal or less likely to be compliant with treatment.

Result of results found for within.

The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial.

Psychopathology – positive symptoms, negative symptoms, depression, agitation-excitement, disorganisation 2. Evid Based Ment Health. Loss of retention can be the result of insufficient clinical effect, or lack of tolerability or acceptance.

This outcome is assessed at regular time intervals until 12 months after recruitment. Home Who are we? Diagnosis of schizophrenia; 2. The presence of one or more of the contraindications against any of the study drugs. Eligibility Participant inclusion criteria 1. Ethics approval Ethics approval received from the local medical ethics committee Study design Multicentre, randomised active controlled, parallel group trial Primary study design Interventional Secondary study design Randomised controlled trial Trial setting Hospitals Trial type Treatment Patient information sheet Condition Schizophrenia, schizophreniform, or schizoaffective disorder Intervention Drug: Quality of life 6.

  DAVID BRIN SUNDIVER PDF

Rationale and design of the trial. Secondary measures include changes in different dimensions of psychopathology, side effects, compliance, social needs, quality of life, substance abuse and cognitive functions. Multicentre, randomised active controlled, parallel group trial.

What is the effectiveness of low doses of haloperidol and regular doses of eufsst, olanzapine, quetiapine, and ziprasidone on loss of one year retention in patients with recent onset of schizophrenia, schizoaffective, and schizophreniform disorder?

Genetic determinants of response to antipsychotic drugs 9. The presence of one or more of the contra-indications against any of the study drugs. Analysis was by intention to treat.

Previous Trial Back to results Next Trial. Ethics approval received from the local medical ethics committee. Intolerance to one of the drugs in this study; 4.

Second-generation antipsychotic drugs were introduced over a decade ago for the treatment of schizophrenia; however, their purported clinical effectiveness compared with first-generation antipsychotic drugs is still debated. Most studies comparing second generation antipsychotics with classical neuroleptics have been conducted in more or less chronic schizophrenia fufest. Effectiveness of antipsychotic drugs in first-episode schizophrenia srudy schizophreniform disorder: We did an open randomised controlled trial of haloperidol versus second-generation antipsychotic drugs in 50 sites, in 14 countries.